Product information
| Price | €175, €275, €395 |
|---|---|
| Size | 20 µl/µg | 50 µl/µg | 100 µl/µg |
| Short name | uPA Antibody |
| Host | Rabbit |
| Isotype | IgG |
| Target protein | PLAU |
| Recommended applications | ELISA, IHC-p |
| Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from human uPA. AA range:190-239 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Formulation | Liquid in PBS containing 50% glycerol; 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Product code | MB-AP13829 |
Additional information
Prev
Next
PLAU (plasminogen activator, urokinase) encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in PLAU may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.
PLAU, Urokinase-type plasminogen activator, U-plasminogen activator, uPA
Human: P00749, Mouse: P06869
Human: 5328
